Transine Therapeutics poised for growth with new CSO hire and tripling of lab space

Thu, Jun 23, 2022

Transine Therapeutics today announced the appointment of Andy Billinton as Chief Scientific Officer as it triples its facility footprint at The Babraham Research Campus.

<

Transine Therapeutics Announces Final Closing of its Seed Round at £13.7m to Accelerate its Platform and Portfolio Development

Tue, May 31, 2022

Company adds £4.6m additional seed funding. Strengthens investor syndicate with Epidarex joining as a new investor. Enhances ability to leverage unique SINEUP® platform and rapidly advance product development programmes.

<

Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO

Mon, Jul 5, 2021

Transine Therapeutics today announced the appointment of Jan Thirkettle, Ph.D. as its Chief Executive Officer.

<

Transine Therapeutics Closes Seed Funding of £9.1 million

Tue, Jun 1, 2021

Transine Therapeutics announces that it successfully secured £9.1 million in seed funding.

<

Transine founders identify key mechanisms of SINEUP® action

Fri, Jan 1, 2021

Transine co-founder, Professor Piero Carninci’s lab recently contributed new seminal understandings to the SINEUP® field.

<

Head of Licensing recognised as one of 2020 Movers and Shakers in BioBusiness

Tue, Nov 10, 2020

The Movers and Shakers in BioBusiness report was released in advance of the BioBeat20 Summit: Accelerating Data-driven Health, on Tuesday 17th November 2020, in partnership with the Francis Crick Institute.

<

BIO-Europe: VP of R&D and Operations discusses the future of neurodegeneration treatment

Thu, Oct 22, 2020

Dr. Sarah Cole, our VP of R&D and Operations, was invited to participate in an expert panel as part of the BIO-Europe conference.

<